Sol Gel Technologies Ltd (SLGL)

Sep 20, 2026

Sol-Gel Technologies announced the completion of the last patient last visit in its pivotal Phase 3 clinical trial for SGT-610, an investigational treatment for Gorlin syndrome. This milestone signifies the end of the patient treatment and follow-up phase, with top-line results expected in late November 2026. SGT-610 aims to prevent basal cell carcinoma lesions in Gorlin syndrome patients, addressing a significant unmet medical need.

Sep 17, 2026

Sol-Gel Technologies (SLGL) has recently formed a 'hammer chart pattern' after an 8.3% stock loss, indicating a potential trend reversal due to exhausted selling pressure and emerging buying interest. This technical signal is supported by strong fundamental factors, including a 33.4% increase in consensus EPS estimates for the current year and a Zacks Rank #2 (Buy), suggesting outperformance potential. Investors are advised to consider SLGL for "bottom fishing" given these combined bullish indicators.